Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma
Copyright policy )Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma
The BOLT study was sponsored and funded by Novartis; this analysis was funded by Sun Pharma. Medical writing and editorial support were funded by Sun Pharma Europe B.V.
Resistencia secundaria; Carcinoma basocelular localmente avanzado
Resistència secundària; Carcinoma basocel·lular localment avançat
Secondary resistance; Locally advanced basal cell carcinoma
Other subheadings::Other subheadings::Other subheadings::/drug therapy, Other subheadings::Other subheadings::Other subheadings::/adverse effects, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Basal Cell, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma basocelular, Carcinoma basocel·lular - Tractament, Letter to the Editor, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
Other subheadings::Other subheadings::Other subheadings::/drug therapy, Other subheadings::Other subheadings::Other subheadings::/adverse effects, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Basal Cell, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma basocelular, Carcinoma basocel·lular - Tractament, Letter to the Editor, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!